193 related articles for article (PubMed ID: 7202370)
1. [Pharmacokinetics of cyclophosphamide and cyclophosphamide metabolites in the mouse and their influence on the therapeutic effect of "activated" cyclophosphamide (4-hydroxycyclophosphamide) (author's transl)].
Voelcker G; Haeglsperger R
Arzneimittelforschung; 1982; 32(6):639-47. PubMed ID: 7202370
[TBL] [Abstract][Full Text] [Related]
2. Nonlinear pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide/aldophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation.
Chen TL; Kennedy MJ; Anderson LW; Kiraly SB; Black KC; Colvin OM; Grochow LB
Drug Metab Dispos; 1997 May; 25(5):544-51. PubMed ID: 9152592
[TBL] [Abstract][Full Text] [Related]
3. Half-life of oxazaphosphorines in biological fluids.
Sladek NE; Powers JF; Grage GM
Drug Metab Dispos; 1984; 12(5):553-9. PubMed ID: 6149904
[TBL] [Abstract][Full Text] [Related]
4. Conversion of 4-hydroperoxycyclophosphamide and 4-hydroxycyclophosphamide to phosphoramide mustard and acrolein mediated by bifunctional catalysis.
Low JE; Borch RF; Sladek NE
Cancer Res; 1982 Mar; 42(3):830-7. PubMed ID: 7059981
[TBL] [Abstract][Full Text] [Related]
5. [Effective levels of cyclophosphamide and metabolites in pleural effusions during intravenous therapy (author's transl)].
Wagner T; Heydrich D
Arzneimittelforschung; 1982; 32(5):566-8. PubMed ID: 7201835
[TBL] [Abstract][Full Text] [Related]
6. Plasma concentrations of 4-hydroxycyclophosphamide and phosphoramide mustard in patients repeatedly given high doses of cyclophosphamide in preparation for bone marrow transplantation.
Sladek NE; Doeden D; Powers JF; Krivit W
Cancer Treat Rep; 1984 Oct; 68(10):1247-54. PubMed ID: 6395951
[TBL] [Abstract][Full Text] [Related]
7. Cyclophosphamide (NSC-26271)-related phosphoramide mustards- recent advances and historical perspective.
Friedman OM; Wodinsky I; Myles A
Cancer Treat Rep; 1976 Apr; 60(4):337-46. PubMed ID: 1277209
[TBL] [Abstract][Full Text] [Related]
8. [Blood level and urinary excretion of activated cyclophosphamide and its deactivation products in man (author's transl)].
Wagner T; Heydrich D; Voelcker G; Hohorst HJ
J Cancer Res Clin Oncol; 1980 Jan; 96(1):79-92. PubMed ID: 7358774
[TBL] [Abstract][Full Text] [Related]
9. Identification and pharmacokinetics of cyclophosphamide (NSC-26271) metabolites in vivo.
Voelcker G; Wagner T; Hohorst HJ
Cancer Treat Rep; 1976 Apr; 60(4):415-22. PubMed ID: 1277216
[TBL] [Abstract][Full Text] [Related]
10. Involvement of human glutathione S-transferase isoenzymes in the conjugation of cyclophosphamide metabolites with glutathione.
Dirven HA; van Ommen B; van Bladeren PJ
Cancer Res; 1994 Dec; 54(23):6215-20. PubMed ID: 7954469
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of cyclophosphamide (CP) and 4-OH-CP/aldophosphamide in systemic vasculitis.
Belfayol-Pisanté L; Guillevin L; Tod M; Fauvelle F
Fundam Clin Pharmacol; 2000; 14(4):415-21. PubMed ID: 11030450
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of 4-hydroxycyclophosphamide and metabolites in the rat.
Hong PS; Srigritsanapol A; Chan KK
Drug Metab Dispos; 1991; 19(1):1-7. PubMed ID: 1673381
[TBL] [Abstract][Full Text] [Related]
13. [Effect of damaged liver parenchyma, renal insufficiency and hemodialysis on the pharmacokinetics of cyclophosphamide and its activated metabolites].
Wagner T; Heydrich D; Bartels H; Hohorst HJ
Arzneimittelforschung; 1980; 30(9):1588-92. PubMed ID: 7193030
[TBL] [Abstract][Full Text] [Related]
14. Cyclophosphamide and 4-Hydroxycyclophosphamide/aldophosphamide kinetics in patients receiving high-dose cyclophosphamide chemotherapy.
Anderson LW; Chen TL; Colvin OM; Grochow LB; Collins JM; Kennedy MJ; Strong JM
Clin Cancer Res; 1996 Sep; 2(9):1481-7. PubMed ID: 9816324
[TBL] [Abstract][Full Text] [Related]
15. Clinical pharmacokinetics of cyclophosphamide and metabolites with and without SR-2508.
Chan KK; Hong PS; Tutsch K; Trump DL
Cancer Res; 1994 Dec; 54(24):6421-9. PubMed ID: 7987837
[TBL] [Abstract][Full Text] [Related]
16. Cytotoxic activity relative to 4-hydroxycyclophosphamide and phosphoramide mustard concentrations in the plasma of cyclophosphamide-treated rats.
Powers JF; Sladek NE
Cancer Res; 1983 Mar; 43(3):1101-6. PubMed ID: 6825082
[No Abstract] [Full Text] [Related]
17. [Intracavitary chemotherapy of S 180 ascites sarcoma in mice with 4-(S-ethanol)-sulfido-cyclophosphamide in combination with protector thiols].
Voelcker G; Jaschke A; Wrabetz E; Hohorst HJ
Arzneimittelforschung; 1984; 34(10):1291-8. PubMed ID: 6440565
[TBL] [Abstract][Full Text] [Related]
18. Accelerated decomposition of 4-hydroxycyclophosphamide by human serum albumin.
Kwon CH; Maddison K; LoCastro L; Borch RF
Cancer Res; 1987 Mar; 47(6):1505-8. PubMed ID: 3815352
[TBL] [Abstract][Full Text] [Related]
19. Biologic activity of two derivatives and six possible metabolites of cyclophosphamide (NSC-26271).
Lelieveld P; van Putten LM
Cancer Treat Rep; 1976 Apr; 60(4):373-9. PubMed ID: 1064468
[TBL] [Abstract][Full Text] [Related]
20. Isolation and mass spectral identification of blood metabolites of cyclophosphamide: evidence for phosphoramide mustard as the biologically active metabolite.
Struck RF; Kirk MC; Witt MH; Laster WR
Biomed Mass Spectrom; 1975 Feb; 2(1):46-52. PubMed ID: 1131393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
